Product Images Duloxetine DR

This is a medication package of Duloxetine 20mg Capsule DR with 30 capsules. It contains an NDC code of 80425-0311-01 and the lot number is 000000000. The package expires on 10/31/2024 and also includes a serial number of 000000138240. The rest of the text does not provide any useful information.*

This is a description of a medication called Duloxetine 20mg capsule DR. The packaging contains 60 capsules and has been assigned a lot number (X000000K) with an expiry date of 10/31/2024. The medication was packed by a company called Boemarasc TR and has been assigned a serial number of 000000138244.*

This is a description of a medication package containing Duloxetine 20mg capsules, a generic alternative to the brand name Cymbalta. The package contains 90 capsules and the lot number is 0000001 38248. The expiration date is October 31st, 2023. The remaining text is not available or not readable.*

This is a graph showing the number of patients experiencing relapse over time from randomization to relapse in days while being treated with either placebo or Duloxetine. The x-axis shows the time from randomization to relapse in days, and the y-axis shows the number of patients. The graph includes two lines, one for the placebo and the other for Duloxetine.*

This appears to be a chart showing the percentage of patients who improved with different treatments of duloxetine at various doses. The chart compares 60mg of duloxetine taken twice daily versus 60mg taken once daily, as well as a placebo. It also displays the percent improvement in pain from the baseline.*

This is a description of a clinical trial that involves the use of Duloxetine, a medication used for the treatment of depression and anxiety disorders. The medication is administered at a dosage of either 60 or 120 mg once daily. The text includes a chart indicating the percent improvement in pain from baseline. The word "Placebo" at the beginning suggests that the trial might involve a placebo control group.*

This is a chart showing the proportion of patients with relapse over time from randomization to relapse (in days) for patients with placebo and duloxetine treatment.*